Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.37 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.37 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.37 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.37 |
| ▸ | MAP3K2 | Q9Y2U5 | 2/20 | 0.37 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.37 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3065623 | 0.91 | LMNA (0.42) | P2RX3 | |
| SCHEMBL8078748 | 0.84 | SMN1; SMN2 (0.38) | P2RX3 | |
| SCHEMBL3054312 | 0.80 | ALDH1A1 (0.43) | NAMPT | |
| SCHEMBL3058652 | 0.74 | P2RX3 (0.36) | P2RX3MAPK14MAPK11DDR1DDR2 | |
| SCHEMBL3044391 | 0.73 | SMN1; SMN2 (0.47) | EPHX2NAMPT | |
| SCHEMBL3053596 | 0.72 | EP300 (0.42) | EPHX2EP300CREBBPCNR1CNR2 | |
| SCHEMBL1025307 | 0.71 | KMT2A (0.46) | NAMPT | |
| SCHEMBL3060167 | 0.71 | SMN1; SMN2 (0.47) | NAMPT | |
| SCHEMBL28806104 | 0.70 | TACR3 (0.58) | — | |
| SCHEMBL3054218 | 0.70 | HTT (0.49) | EPHX2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261710-A1 | HDAC Inhibitors | ARQULE, INC. (US) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261710-A1 | HDAC Inhibitors | HDAC5, HDAC1, HDAC4 | P2RX3 4527/4885MAPK14 2332/4885MAPK11 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.